Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 1, 2013, Pages 17-22

  Matavelli, Luis C ^a   Siragy, Helmy M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

aldosterone; amlodipine; diabetes; kidney; oxidative stress; renal fibrosis

Indexed keywords

8 ISOPROSTANE; ALDOSTERONE; ALISKIREN; AMLODIPINE; CYCLIC GMP; FIBRONECTIN; GLUCOSE; NITRIC OXIDE; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HORMONE SYNTHESIS; IMMUNOHISTOCHEMISTRY; INTERSTITIAL FLUID; KIDNEY FIBROSIS; KIDNEY INJURY; MALE; NONHUMAN; OXIDATIVE STRESS; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; RAT; SODIUM URINE LEVEL; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINE VOLUME;

ALDOSTERONE; AMIDES; AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CYCLIC GMP; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DINOPROST; DOWN-REGULATION; FIBRONECTINS; FIBROSIS; FUMARATES; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; NATRIURESIS; NITRIC OXIDE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84872292672     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318274d2ef     Document Type: Article

References (37)

1. Hollenberg NK, Stevanovic R, Agarwal A, et al. Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int. 2004; 65:1435-1439.
2. Siragy HM, Awad A, Abadir P, et al. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats. Endocrinology. 2003;144:2229-2233.
3. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63: 1791-1800.
4. Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes. 2010;17:199-204.
5. Ikeda U, Kanbe T, Nakayama I, et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1B. Eur J Pharmacol. 1995;290:69-73.
6. Maron BA, Zhang YY, Handy DE, et al. Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. J Biol Chem. 2009;284:7665-7672.
7. Iglarz M, Touyz RM, Viel EC, et al. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. Am J Hypertens. 2004;17:597-603.
8. Practico D, Lawson JA, Roakach J, et al. The isoprostanes in biology and medicine. Trends Endocrinol Metab. 2001;12:243-247.
9. Onozato ML, Tojo A, Kobayashi N, et al. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant. 2007;22:1314-1322.
10. Huang S, Zhang A, Ding G, et al. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am J Physiol Renal Physiol. 2009;296:F1323-F1333.
11. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465.
12. Schjoedt KJ, Andersen S, Rossing P, et al. Aldosterone escape during blockade of the renin-angiotensin system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47:1936-1939.
13. Persson F, Lewis JB, Lewis EJ, et al. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. J Renin Angiotensin Aldosterone Syst. 2012; 13:118-121.
14. Nadler JL, Hsueh W, Horton R. Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab. 1985;60:896-899.
15. Aguilera G, Catt KJ. Participation of voltage-dependent calcium channels in the regulation of adrenal glomerulosa function by angiotensin II and potassium. Endocrinology. 1986;118:112-118.
16. Zhou MS, Jaimes EA, Raij L. Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats. J Cardiovasc Pharmacol. 2006;48:857-861.
17. Mohler ER III, Herrington D, Ouyang P, et al; EXPLORE Investigators. A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure. J Clin Hypertens (Greenwich). 2006;8:692-698.
18. Toblli JE, Ferder L, Angerosa M, et al. Effects of amlodipine on tubulointerstitial lesions in normotensive hyperoxaluric rats. Hypertension. 1999,34:254-258.
19. Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazeprilamlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47:636-642.
20. Matavelli LC, Huang J, Siragy HM. Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. J Cardiovasc Pharmacol. 2012;59:281-287.
21. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997; 100:264-269.
22. Kokolakis G, Panagis L, Stathopoulos E, et al. From the protein to the graph: how to quantify immunohistochemistry staining of the skin using digital imaging. J Immunol Methods. 2008;331:140-146.
23. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6:261-273.
24. Siragy HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol. 2008;93:817-824.
25. Brovkovych V, Kalinowski L, Muller-Peddinghaus R, et al. Synergistic antihypertensive effects of nifedipine on endothelium: concurrent release of NO and scavenging of superoxide. Hypertension. 2001;37:34-39.
26. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97:576-580.
27. Taddei S, Virdis A, Ghiadoni L, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension. 2001;37:943-948.
28. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: ENCORE I study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation. 2003;107:422-428.
29. Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren inproves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008;52:563-572.
30. Ikeda U, Shimpo M, Ohki R, et al. Amlodipine increases nitric oxide synthesis in cytokine-stimulated cultured vascular smooth muscle cells. J Hypertens. 2000;18:1597-1604.
31. Kim J, Seok YM, Jung KJ, et al. Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice. Am J Physiol Renal Physiol. 2009;297:F461-F470.
32. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433-442.
33. Nishiyama A, Yao L, Nagai Y, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004;43:841-848.
34. Neves MF, Amiri F, Virdis A, et al; CIHR Multidisciplinary Research Group on Hypertension. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol. 2005;83:999-1006.
35. Susic D, Varagic J, Ahn S, et al. Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol. 2007;292;H175-H179.
36. Lea WB, Kwak ES, Luther JM, et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 2009;75:936-944.
37. Fiebeler A, Nussberger J, Shagdarsuren E, et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005;111:3087-3094.